[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 5 sources · 2 days · First seen · Last updated

Advancements in cancer immunotherapy and targeted treatments

Overview

Recent developments in oncology research highlight progress in targeted cancer therapies and vaccines.

The Cancer Vaccine Institute has initiated Phase II clinical trials for STEMVAC, an investigational vaccine for metastatic triple-negative breast cancer. The study, led by Dr. Brie Chun, tests the vaccine in combination with chemotherapy to target proteins on breast cancer stem cells, specifically for patients who are PD-L1-negative.

Separately, Verastem Oncology reported results from its Phase 1/2 TARGET-D 101 trial for VS-7375, an oral KRAS G12D inhibitor. The drug showed antitumor activity in patients with metastatic pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Following these results, the company has reached an agreement with the FDA to begin Phase 3 clinical trials for VS-7375 focusing on first-line metastatic pancreatic cancer.

Entities

Barbara Ann Karmanos Cancer Institute · VS-7375 · STEMVAC · Verastem Oncology · Cancer Vaccine Institute

Timeline

  1. [HEALTH] 2 sources
    Verastem Oncology reports VS-7375 efficacy in KRAS G12D tumor trials

    Verastem Oncology's KRAS G12D inhibitor, VS-7375, showed efficacy in treating pancreatic, colorectal, and lung cancers in phase 1/2 trials, leading to FDA alignment for a phase 3 trial in pancreatic cancer.

  2. [HEALTH] 3 sources
    STEMVAC vaccine enters Phase II clinical trials for triple-negative breast cancer

    A Phase II clinical trial is underway for STEMVAC, an investigational vaccine targeting metastatic triple-negative breast cancer, particularly for patients who do not respond to standard immunotherapy.

Sources

blackdoctor.org · cancernetwork.com · newsable.asianetnews.com · seekingalpha.com · uwcvi.org